If You Had Bought Insmed Shares Three Years Ago You’d Have Made 124%

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. For instance the Insmed Incorporated (NASDAQ:INSM) share price is 124% higher than it was three years ago. That sort of return is as solid as granite. On top of that, the share price is up 52% in about a quarter.

See our latest analysis for Insmed

Insmed didn’t have any revenue in the last year, so it’s fair to say it doesn’t yet have a proven product (or at least not one people are paying for). So it seems that the investors more focused on would could be, than paying attention to the current revenues (or lack thereof). We’d posit some have faith that Insmed has the funding to invent a new product before too long.

As a general rule, if a company doesn’t have revenue, and it loses money, then it is a high risk investment. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). Some Insmed investors have already had a taste of the sweet taste stocks like this can leave in the mouth, as they gain popularity and attract speculative capital

When it reported in September 2018 Insmed had minimal net cash consider its expenditure: just US$197m to be specific. So if it has not already moved to replenish reserves, we think the near-term chances of a capital raising event are pretty high. Given how low on cash the it got, investors must really like its potential for the share price to be up 31% per year, over 3 years. You can see in the image below, how Insmed’s cash and debt levels have changed over time (click to see the values).

NasdaqGS:INSM Historical Debt, February 21st 2019
NasdaqGS:INSM Historical Debt, February 21st 2019

It can be extremely risky to invest in a company that doesn’t even have revenue. There’s no way to know its value easily. Given that situation, many of the best investors like to check if insiders have been buying shares. It’s often positive if so, assuming the buying is sustained and meaningful. You can click here to see if there are insiders buying.

A Different Perspective

It’s good to see that Insmed has rewarded shareholders with a total shareholder return of 6.6% in the last twelve months. That gain is better than the annual TSR over five years, which is 4.9%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. The data on insider buying is an obvious place to start. You can click here to see who has been buying shares – and the price they paid.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.